LSL Pharma Group Inc. (TSXV:LSL)

LSL Pharma Group Balance Sheet

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jul 31, 2021
Cash & Equivalents	0.45	0.3	0.01	0.01	-
Cash & Short-Term Investments	0.45	0.3	0.01	0.01	-
Cash Growth	173.78%	3600.00%	-	-	-
Accounts Receivable	5.89	4.95	2.68	1.23	-
Other Receivables	-	-	-	-	0.02
Total Trade Receivables	5.89	4.95	2.68	1.23	0.02
Inventory	13.39	9.22	4.11	2.96	-
Other Current Assets	0.93	1.02	0.41	0.21	-
Total Current Assets	20.66	15.48	7.2	4.4	0.02
Net Property, Plant & Equipment	24.75	22.94	14.75	13.92	-
Other Intangible Assets	14.33	13.27	8.93	8.98	-
Goodwill	0.16	0.16	-	-	-
Other Long-Term Assets	0.3	1.77	0.02	0.02	-
Total Assets	60.19	53.61	30.9	27.31	0.02
Accounts Payable	4.12	5.3	5.98	6.12	0.09
Short-Term Debt	8.04	2.56	3.77	3.78	0.11
Current Portion of Long-Term Debt	0.9	1.45	5.22	1.58	-
Current Portion of Leases	0.48	0.45	0.12	0.14	-
Unearned Revenue	-	-	-	0.01	-
Total Current Liabilities	13.54	9.75	15.07	11.62	0.2
Long-Term Debt	15.43	12.75	4.73	7.84	-
Long-Term Leases	4.06	4.43	2.44	2.56	-
Other Long-Term Liabilities	1.79	1.79	-	-	-
Total Long-Term Liabilities	21.27	18.97	7.17	10.4	-
Total Liabilities	34.81	28.72	22.25	22.02	0.2
Common Stock	38.45	36.39	24.2	15.05	2.93
Additional Paid-in Capital	3.57	3.42	2.69	-	0.45
Retained Earnings	-16.64	-14.92	-18.23	-9.76	-3.56
Shareholders' Equity	25.38	24.89	8.66	5.29	-0.19
Total Liabilities & Equity	60.19	53.61	30.9	27.31	17.31
Total Debt	28.91	21.64	16.27	15.9	0.11
Net Cash (Debt)	-28.46	-21.34	-16.26	-15.89	-0.11
Net Cash Per Share	-0.25	-0.20	-0.20	-0.24	-
Book Value	25.38	24.89	8.66	5.29	-0.19
Book Value Per Share	0.22	0.24	0.11	0.08	-
Tangible Book Value	10.89	11.46	-0.28	-3.69	-0.19
Tangible Book Value Per Share	0.09	0.11	-0.00	-0.05	-

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.